Interesting results. Now if the FDA would only approve the GA68 PSMA PET scan but, even if they do, it’s still pretty iffy on detecting cancer with my PSA level hanging out in the 0.10-0.13 range.
According to a presentation given yesterday at the ASCO meeting here in Chicago, PET/CT scanning with 68Ga-PSMA-11 is more accurate than 18F-fluciclovine PET/CT at detecting recurrent prostate cancer in men with early biochemical recurrence following radical prostatectomy.
Basically, Calais and his colleagues carried out a prospective, single-center, single-arm, head-to-head Phase III study of paired 18F-fluciclovine (FACBC) and 68Ga-PSMA-11 (PSMA) PET/CT scans for localizing early biochemical recurrence (BCR) of prostate cancer in men who had previously undergone a radical prostatectomy.
The trial enrolled 50 consecutive patients with BCR and PSA levels ranging from ≥ 0.2 to ≤ 2.0 ng/ml who had not had any salvage therapy at the time they were scanned. All 50 patients were given…
View original post 304 more words